A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis

The British Journal of Dermatology
J LauharantaA Lassus

Abstract

Eighty ambulatory adult patients with severe psoriasis were included in our 14-week study to compare the clinical effects of treatment with an aromatic retinoid (Tigason), combination treatment with aromatic retinoid plus PUVA (RePUVA), and PUVA alone. RePUVA was given by two different modifications: either 4 weeks of pretreatment with retinoid followed by 6 weeks of PUVA treatment, or 10 weeks of retinoid treatment with concomitant PUVA treatment during the last 6 weeks. The latter modification of RePUVA proved to be significantly more effective than the other treatments (P less than 0.01) as regards complete remission. With respect to the number of patients with good or excellent improvement (75-100% improvement) there was no marked difference between RePUVA and PUVA treatments. Retinoid alone proved to be the least effective, showing, however, a good to excellent result in 65% of patients. Besides the increase in efficacy, another advantage achieved by RePUVA was a highly significant (P less than 0.001) reduction of total UVA doses to about one third as compared to PUVA therapy.

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Apr 12, 1979·The New England Journal of Medicine·R S SternT B Fitzpatrick
May 4, 1979·Archives of Dermatological Research·G Heidbreder, E Christophers
Dec 1, 1979·The British Journal of Dermatology·C HofmannO Braun-Falco
Aug 1, 1977·The Australasian Journal of Dermatology·J H Epstein
Apr 1, 1978·The Journal of Investigative Dermatology·P O FritschK Wolff
Jun 1, 1977·The Journal of Investigative Dermatology·J W MelskiH L Bleich
Dec 5, 1974·The New England Journal of Medicine·J A ParrishM A Pathak
Feb 1, 1980·The British Journal of Dermatology·A Lassus

❮ Previous
Next ❯

Citations

Jan 1, 1982·Archives of Dermatological Research·J Lauharanta, U Paravicini
Jan 19, 2013·American Journal of Clinical Dermatology·Cheryl J GustafsonSteven R Feldman
Apr 11, 2013·American Journal of Clinical Dermatology·Fahad AlmutawaHenry W Lim
Jan 1, 1987·Pharmacology & Therapeutics·M T McEvoy, R S Stern
Jan 1, 1989·Pharmacology & Therapeutics·H Hönigsmann, K Wolff
Jan 1, 1989·Pharmacology & Therapeutics·L MattN J Lowe
Oct 6, 1997·Clinics in Dermatology·P C van de Kerkhof
Oct 6, 1997·Clinics in Dermatology·J Lauharanta
Jun 26, 2001·Clinical and Experimental Dermatology·P C van de Kerkhof
Oct 28, 2003·The Journal of Dermatological Treatment·P I SpulsM Lebwohl
Dec 9, 1997·The British Journal of Dermatology·S MuchenbergerJ C Simon
Feb 1, 1994·The British Journal of Dermatology
Jun 1, 1990·The British Journal of Dermatology·B Halioua, J H Saurat
Jan 1, 1985·Journal of the American Academy of Dermatology·N VäätäinenJ E Fräki
Nov 1, 1987·Journal of the American Academy of Dermatology·A K Gupta, T F Anderson
Mar 1, 1983·Journal of the American Academy of Dermatology·E M FarberA Charuworn
Jul 1, 1982·Journal of the American Academy of Dermatology·R J Coskey
May 26, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·E ArchierM-A Richard
Feb 1, 1996·Journal of the American Academy of Dermatology·M A MenterM D Zanolli
Jun 1, 1989·The British Journal of Dermatology·S ReitamoA Lassus
Dec 1, 1988·The British Journal of Dermatology·A Lassus, J M Geiger
Dec 1, 1988·The British Journal of Dermatology·C GreenB E Johnson
Oct 1, 1983·The Journal of Dermatology·H IshizakiT Hirone
Oct 1, 1988·International Journal of Dermatology·E Darouti, A Rubaie
Sep 1, 1981·The British Journal of Dermatology·J LauharantaK Mustakallio
Mar 1, 1987·Clinical and Experimental Dermatology·R A Logan
Sep 1, 1985·The British Journal of Dermatology·L DubertretR Touraine
Nov 1, 1985·Clinical and Experimental Dermatology·T PiamphongsantP Gritiyarangsan
Jan 1, 1985·Annals of the New York Academy of Sciences·J A ParrishR W Gange
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A Arechalde, J H Saurat
Feb 5, 1990·The Medical Journal of Australia·H Rotstein, C Baker
Jun 1, 1991·The Journal of Investigative Dermatology·Y TokuraF P Gasparro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.